The American Enterprise Institute released a report that detailed several proposals of change for the ACA that could possibly be implemented with the next president. Joe Antos, PhD, the Wilson H. Taylor Scholar in Health Care and Retirement Policy at the American Enterprise Institute, said that though these changes would depend on the party in office, implementing them wouldn’t necessarily be easy.
The American Enterprise Institute released a report that detailed several proposals of change for the ACA that could possibly be implemented with the next president. Joe Antos, PhD, the Wilson H. Taylor Scholar in Health Care and Retirement Policy at the American Enterprise Institute, said that though these changes would depend on the party in office, implementing them wouldn’t necessarily be easy.
Transcript (slightly modified)
Do you think change to the ACA is possible at this point? Do you think the proposals put forth in the American Enterprise Institute’s report could possibly be implemented with the next president?
Well I think change is inevitable. The question is, is it going in a reasonable direction or a bad direction? And, is it conscious or unconscious? So I agree that certainly the report that we did with as many proposals as we put forth, something like that is impossible no matter who the president is. It’s too big, it’s simply too big.
However, parts of those proposals, there are aspects of those ideas that I think would be compelling to certainly a republican in office and I think some of those ideas would be accepted by a democrat as well. Not the whole package but some changes. And those changes will probably be more forced by reality than something that you want to do because it seems like a good idea. We’re going to have financial difficulties, we’re going to have continuing problems with access, and these are issues that need to be dealt with.
Health Care Utilization and Cost of Diagnostic Testing for Respiratory Infections
September 17th 2025Syndromic reverse transcriptase–polymerase chain reaction tests for respiratory infections were associated with lower health care resource utilization and costs, implicating potential for improved value in patient care.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More